Effects of Reoperation Timing on Survival among Recurrent Glioblastoma Patients: A Retrospective Multicentric Descriptive Study

被引:3
|
作者
Kalita, Ondrej [1 ,2 ]
Kazda, Tomas [3 ]
Reguli, Stefan [4 ]
Jancalek, Radim [5 ]
Fadrus, Pavel [6 ]
Slachta, Marek [1 ]
Pospisil, Petr [3 ]
Krska, Lukas [4 ]
Vrbkova, Jana [7 ]
Hrabalek, Lumir [1 ]
Smrcka, Martin [6 ]
Lipina, Radim [4 ]
机构
[1] Palacky Univ Olomouc, Univ Hosp Olomouc, Fac Med & Dent, Dept Neurosurg, Zdravotniku 248 7, Olomouc 77900, Czech Republic
[2] T Bata Univ Zlin, Fac Humanities, Dept Hlth Care Sci, Stefanikova 5670, Zlin 76001, Czech Republic
[3] Masaryk Univ, Masaryk Mem Canc Inst, Fac Med, Dept Radiat Oncol, Zluty Kopec 7, Brno 65653, Czech Republic
[4] Univ Ostrava, Univ Hosp Ostrava, Fac Med, Dept Neurosurg, 17 Listopadu 1790 5, Ostrava 70852, Czech Republic
[5] Masaryk Univ, St Annes Univ Hosp Brno, Fac Med, Dept Neurosurg, Pekarska 664 53, Brno 60200, Czech Republic
[6] Masaryk Univ, Univ Hosp Brno, Fac Med, Dept Neurosurg, Jihlavska 20, Brno 62500, Czech Republic
[7] Palacky Univ Olomouc, Inst Mol & Translate Med, Fac Med & Dent, Hnevotinska 133 5, Olomouc 77900, Czech Republic
关键词
glioblastoma; reoperation timing; treatment strategy; PHASE-II TRIAL; CENTRAL-NERVOUS-SYSTEM; ADJUVANT TEMOZOLOMIDE; MULTIPLE RESECTIONS; SAFE-RESECTION; TUMOR VOLUME; SURGERY; EXTENT; RADIOTHERAPY; MULTIFORME;
D O I
10.3390/cancers15092530
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glioblastoma inevitably recurs, but no standard regimen has been established for treating this recurrent disease. Several reports claim that reoperative surgery can improve survival, but the effects of reoperation timing on survival have rarely been investigated. We, therefore, evaluated the relationship between reoperation timing and survival in recurrent GBM. A consecutive cohort of unselected patients (real-world data) from three neuro-oncology cancer centers was analyzed (a total of 109 patients). All patients underwent initial maximal safe resection followed by treatment according to the Stupp protocol. Those meeting the following criteria during progression were indicated for reoperation and were further analyzed in this study: (1) The tumor volume increased by >20-30% or a tumor was rediscovered after radiological disappearance; (2) The patient's clinical status was satisfactory (KS = 70% and PS WHO = gr. 2); (3) The tumor was localized without multifocality; (4) The minimum expected tumor volume reduction was above 80%. A univariate Cox regression analysis of postsurgical survival (PSS) revealed a statistically significant effect of reoperation on PSS from a threshold of 16 months after the first surgery. Cox regression models that stratified the Karnofsky score with age adjustment confirmed a statistically significant improvement in PSS for time-to-progression (TTP) thresholds of 22 and 24 months. The patient groups exhibiting the first recurrence at 22 and 24 months had better survival rates than those exhibiting earlier recurrences. For the 22-month group, the HR was 0.5 with a 95% CI of (0.27, 0.96) and a p-value of 0.036. For the 24-month group, the HR was 0.5 with a 95% CI of (0.25, 0.96) and a p-value of 0.039. Patients with the longest survival were also the best candidates for repeated surgery. Later recurrence of glioblastoma was associated with higher survival rates after reoperation.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study
    Morisse, M. C.
    Etienne-Selloum, N.
    Bello-Roufai, D.
    Blonski, M.
    Taillandier, L.
    Lorgis, V.
    Noel, G.
    Ahle, G.
    Duran-Pena, A.
    Boone, M.
    Chauffert, B.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2019, 144 (02) : 419 - 426
  • [2] Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study
    M. C. Morisse
    N. Etienne-Selloum
    D. Bello-Roufai
    M. Blonski
    L. Taillandier
    V. Lorgis
    G. Noël
    G. Ahle
    A. Durán-Peña
    M. Boone
    B. Chauffert
    [J]. Journal of Neuro-Oncology, 2019, 144 : 419 - 426
  • [3] Survival after reoperation for recurrent glioblastoma
    Woodroffe, Royce W.
    Zanaty, Mario
    Soni, Neetu
    Mott, Sarah L.
    Helland, Logan C.
    Pasha, Arham
    Maley, Joan
    Dhungana, Neha
    Jones, Karra A.
    Monga, Varun
    Greenlee, Jeremy D. W.
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 73 : 118 - 124
  • [4] A Meta-Analysis of Survival Outcomes Following Reoperation in Recurrent Glioblastoma: Time to Consider the Timing of Reoperation
    Zhao, Yu-Hang
    Wang, Ze-Fen
    Pan, Zhi-Yong
    Peus, Dominik
    Delgado-Fernandez, Juan
    Pallud, Johan
    Li, Zhi-Qiang
    [J]. FRONTIERS IN NEUROLOGY, 2019, 10
  • [5] Survival after reoperation for recurrent glioblastoma multiforme: A prospective study
    Furtak, Jacek
    Kwiatkowski, Artur
    Sledzinska, Paulina
    Bebyn, Marek
    Krajewski, Stanislaw
    Szylberg, Tadeusz
    Birski, Marcin
    Druszcz, Adam
    Krystkiewicz, Kamil
    Gasinski, Piotr
    Harat, Marek
    [J]. SURGICAL ONCOLOGY-OXFORD, 2022, 42
  • [6] Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit
    Tully, Patrick A.
    Gogos, Andrew J.
    Love, Craig
    Liew, Danny
    Drummond, Katharine J.
    Morokoff, Andrew P.
    [J]. NEUROSURGERY, 2016, 79 (05) : 678 - 689
  • [7] Effect of Reoperation on Survival of Patients With Glioblastoma
    Bekar, Ahmet
    Taskapilioglu, Mevlut Ozgur
    Guler, Tugba Morali
    Aktas, Ulas
    Tolunay, Sahsine
    [J]. JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, 2012, 29 (01): : 110 - 116
  • [8] Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma
    Dono, Antonio
    Zhu, Ping
    Holmes, Emma
    Takayasu, Takeshi
    Zhu, Jay-Jiguang
    Blanco, Angel, I
    Hsu, Sigmund
    Bhattacharjee, Meenakshi B.
    Ballester, Leomar Y.
    Kim, Dong H.
    Esquenazi, Yoshua
    Tandon, Nitin
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2022, 156 (02) : 353 - 363
  • [9] Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma
    Antonio Dono
    Ping Zhu
    Emma Holmes
    Takeshi Takayasu
    Jay-jiguang Zhu
    Angel I. Blanco
    Sigmund Hsu
    Meenakshi B. Bhattacharjee
    Leomar Y. Ballester
    Dong H. Kim
    Yoshua Esquenazi
    Nitin Tandon
    [J]. Journal of Neuro-Oncology, 2022, 156 : 353 - 363
  • [10] REGORAFENIB IN RECURRENT GLIOBLASTOMA PATIENTS: A MULTICENTRIC REAL-LIFE STUDY
    Bruno, F.
    Pellerino, A.
    Pronello, E.
    Palmiero, R.
    Polo, V
    Vitaliani, R.
    Trincia, E.
    Interno, V
    Porta, C.
    Soffietti, R.
    Ruda, R.
    [J]. NEURO-ONCOLOGY, 2022, 24